A tau PET study with 18F-THK5351 on neurodegenerative disorders patients.

A tau PET study with 18F-THK5351 on neurodegenerative disorders patients. - A tau PET study with 18F-THK5351 on neurodegenerative disorders patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036956

Enrollment

150

Registered

2019-06-04

Start date

2019-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who are suspected neurodegenerative disorders including Alzheimer disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, frontotemporal lobe degeneration, Parkinson&#39

Interventions

18F-THK5351 and 11C-PiB PET

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have intention to participate in the PET study and are suspected having neurodegenerative disorders.

Exclusion criteria

Exclusion criteria: Patients having history of seizure, alcoholism, or any kind of drug dependency. Patients recognized to be inappropriate by anyone of attending physicians or study staffs.

Design outcomes

Primary

Measure	Time frame
Comparison of the distribution of tau deposit among disorders manifesting parkinsonism or dementia.	—

Secondary

Measure	Time frame
Relationship between clinical pictures and distributions of tau and amyloid deposit.	—

Countries

Japan

Contacts

Public ContactYoshihiko Horimoto

Nagoya City Rehabilitation Agency Department of Neurology

holly@nagoya-rehab.or.jp052-835-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026